BRONCHIECTASIS
Vento | GSK 223977
Sponsor: GlaxoSmithKline (GSK)
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis.
NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFBE)
Verona 220 | RPL554-NCFB-220
Sponsor: Verona Pharma
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with Non-cystic Fibrosis Bronchiectasis (NCFBE).
CSL787
Sponsor: CSL Behring
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Nebulized CSL787 in Healthy Subjects and Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB).
Interested in Learning More About Bronchiectasis Trials?
Submit your information and our team will follow up within 24–48 hours.
What Can I Expect if I Enroll?
If you are interested in learning more or enrolling, our staff will contact you within a few days.
There is no obligation, and your information will be kept confidential. Our staff will:
- Screen interested participants for eligibility in active clinical trials
- Determine whether you may qualify for participation
- Explain study details, including protocol, duration, and compensation (varies by study)
- Provide clear guidance on the study process from start to finish and answer any questions
- Communicate with your established physician, as appropriate, regarding your participation
- Patient enrollment and participation are voluntary and may be discontinued at any time
Patients enrolled in our clinical trials remain under the care of their established physician for routine healthcare.
Simply provide your contact information, and our staff will guide you through the next steps.